ArticleJournal of Taibah University Medical Sciences2026
Biological evaluation of resin-modified glass ionomer cement containing coumarin derivatives for dental application.
Article in Journal of Taibah University Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the cytotoxic effects of resin modified glass ionomer cement (RMGIC) incorporated with coumarin derivatives 3-acetylcoumarin (AC) and coumarin thiosemicarbazone (CT) on human periodontal ligament fibroblast (HPdLF) cells and the antibacterial activities thereof against cariogenic bacteria. Methods: RMGIC-AC and RMGIC-CT were synthesized by incorporating AC and CT, respectively, in RMGIC at compositions 0.5 %, 1.0 % and 1.5 % by weight. The chemical functional groups in RMGIC-coumarins were identified by Fourier Transform Infrared (FTIR) spectroscopy. The cytotoxicity effects of RMGIC-coumarins were evaluated in the HPdLF cell line using MTT assay for 72 h. Broth macrodilution assay was used for the antibacterial evaluation of RMGIC-coumarins against Results: FTIR spectra of the RMGIC-coumarin derivatives detected a lactone group (C[bond, double bond]O) at 1678-1716 cm-1 and an imine stretching (C[bond, double bond]N) at 1602 cm-1. At concentrations of 50 mg/ml or lower, the cytotoxicityof RMGIC-coumarins resulted in more than 70 % cell viability, except for RMGIC-CT at1.5 %. Significant differences in cell viability were observed at concentrations of 50,100, and 200 mg/ml ( Conclusion: RMGIC incorporated with coumarin derivatives at 0.5 % exhibited the most favorable biological performance, achieving an optimal balance between cytotoxicity and antibacterial properties compared with concentrations of 1.0 % and 1.5 %. RMGIC-CT at 0.5 % appeared to be more effective than RMGIC-AC at 0.5 %, as shown by the stronger inhibition of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.